¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Tin and its compounds"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • et al ; and others
    µé, µî. tat<ºÒ>[ÀÇ]»óÅÂ(ßÒ÷¾),
  • et al ; and others
    µé, µî. tat<ºÒ>[ÀÇ]»óÅÂ(ßÒ÷¾), ¼ÒÁú(áÈòõ). tat crible<ºÒ>[¹Ì»ý]»ç»óÅÂ(ÞèßÒ÷¾). tat dexcitation loca
  • explosion and fire hazard
    Æø¹ßÀÎÈ­¼º À§Çè.
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⼺ ¸¸¼º ¿øÆÇ»ó ż±¾ç ÇǺο°
  • familial fructose and galactose intol
    °¡Á·¼º ÇÁ·°Åä¿À½º ¹× °¥¶ôÅä ¿À½º
  • familial fructose and galactose intolerance
    °¡Á·¼º ÇÁ·°Åä¿À½º ¹× °¥¶ôÅä ¿À½º ºÒ³»Àμº(¡­ÝÕÒ±ìÑàõ).
  • feeding and eating disorder
    ¸ÔÀÌ±â ¹× ¸Ô±âÀå¾Ö(º´),¼·½ÄÀå¾Ö(º´)
  • flexure of wrist and hand
  • fluid and hemodynamic derangements
    ü¾× ¹×, Ç÷¿ªÇÐÀå¾Ö
  • fold and fossa
    º¹¸·ÁÖ¸§°ú º¹¸·¿À¸ñ
  • foot and mouth disease
    ¹ßÀÔº´, Á·±¸º´
  • foot and mouth disease
    ±¸Àúº´
  • foot and mouth disease
    ¹ßÀÔº´, Á·±¸º´.
  • foot-and-mouth disease
    ±¸Á¦¿ª (Ï¢ð´æ¹)
  • glioma of optic nerve and chiasm
    ½Ã½Å°æ±³Â÷ ±³¼¼Æ÷Á¾.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SBLA sarcoma, breast and brain tumors, leukemia, laryngeal and lung cancer, and adrenal cortical carcinom...
VACTERL vertebral abnormalities, anal atresia, cardiac abnormalities, tracheoesophageal fistula and/or esoph...
A&A aid and attendance; awake and aware
ABCDES abnormal alignment, bones-periarticular osteoporosis, cartilage-joint space loss, deformities, margi...
ACFAO American College of Foot and Ankle Orthopedics and Medicine
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
PAC Polycyclic aromatic compounds
QAC Quaternary Ammonium Compounds
VOC Volatile Organic Compounds
VSC Volatile sulfur compounds
DHEAS Dehydroepiandrosterone, its sulfate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • normocytic and normochromic anemia
    Á¤ÀûÇ÷±¸¼º ºóÇ÷
  • one : À¯±âÈ­Çп¡¼­ ÄÉÅæÀÌ ÀÖÀ½À» ³ªÅ¸³»´Â Á¢¹Ì¾î.

    one and one-half syndrome

    1°ú 1/2 ÁõÈıº
  • palm and sole system of identification
    ¼öÀå Á·Àú È®Àιý
  • perfusion and diffusion imaging
    °ü·ù È®»ê ¿µ»ó
  • pit and fissure caries
    ¼Ò¿Í ¿­±¸ ¿ì½ÄÁõ
  • pit and fissure lesion
    ¼Ò¿Í ¿­±¸ º´¼Ò
  • post and core crown
    Æ÷½ºÆ® ÄÚ¾î ±Ý°ü
  • proper direction and control
    ÀûÀýÇÑ Áöµµ¿Í ÅëÁ¦
  • pseudoepitheliomatous keratotic and micaceous balanitis
    °¡¼º »óÇÇÁ¾¼º ¼®¸é °¢È­ ±ÍµÎ¿°
  • quick cooling and grinding
    ±Þ³Ã°ú ¿¬¸¶
  • resorption and exfoliation
    Èí¼ö ¹× Å»¶ô±â
  • resuscitation bag and mask
    ¼Ò»ý¿ë ¹é°ú ¸¶½ºÅ©
  • right and left laterotrusive movement
    Á¿ì Ãø¹æ ¿îµ¿
  • right and left margin of uterus
    ¿À¸¥, ¿Þ Àڱà °¡ÀåÀÚ¸®
  • safety regulation and standard
    ¾ÈÀü Á¶Àý ¹× Ç¥ÁØ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
mustard compounds Strong alkylating and immunosuppressive agents whose biological activity is based on the presence of bis(2-chloroethyl)- groups. Although otherwise structurally diverse, the compounds have in common the capacity to contribute alkyl groups to DNA. They are generally highly toxic but include among their number many widely used and effective antineoplastic agent.
(12 Dec 1998)
polychloroterphenyl compounds Compounds consisting of three benzene rings linked to each other in either ortho, meta or para positions and substituted with chlorine atoms.
(12 Dec 1998)
potassium compounds Inorganic compounds that contain potassium as an integral part of the molecule.
(12 Dec 1998)
pralidoxime compounds Various salts of a quaternary ammonium oxime that reconstitute inactivated acetylcholinesterase, especially at the neuromuscular junction, and may cause neuromuscular blockade. They are used as antidotes to organophosphorus poisoning as chlorides, iodides, methanesulfonates (mesylates), or other salts.
(12 Dec 1998)
heterocyclic compounds Ring compounds having atoms other than carbon in their nuclei.
(12 Dec 1998)
heterocyclic compounds, 1-ring A class of organic compounds containing a ring structure made up of more than one kind of atom, usually carbon plus another atom. The ring structure can be aromatic or nonaromatic.
(12 Dec 1998)
heterocyclic compounds, 2-ring A class of organic compounds containing two ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic.
(12 Dec 1998)
heterocyclic compounds, 3-ring A class of organic compounds containing three ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic
(12 Dec 1998)
heterocyclic compounds, bridged-ring A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms.
(12 Dec 1998)
heterocyclic compounds with 4 or more rings A class of organic compounds containing four or more ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic.
(12 Dec 1998)
hexamethonium compounds <chemical> Compounds containing the hexamethylenebis(trimethylammonium) cation. Members of this group frequently act as antihypertensive agents and selective ganglionic blocking agents.
Pharmacological action: antihypertensive agents, ganglionic blockers.
(12 Dec 1998)
high energy compounds Classically, a group of phosphoric esters whose hydrolysis takes place with a standard free energy change of -5 to -15 kcal/mol (or, -20 to -63 kJ/mol) (in contrast to -1 to -4 kcal/mol or, -4 to -17 kJ/mol) for simple phosphoric esters like glucose-6-phosphate or alpha-glycerophosphates), thus being capable of driving energy-consuming reactions in living cells or reconstituted cell-free systems; adenosine 5'-triphosphate, with respect to the beta-and gamma-phosphates, is the best known and is regarded as the immediate energy source for most metabolic syntheses. The general types are acid anhydrides, phosphoric esters of enols, phosphamic acid (R-NH-PO3H2) derivatives, acyl thioesters (e.g., of coenzyme A), sulfonium compound's (R3-S+), and aminoacyl esters of ribosyl moieties.
See: high energy phosphates.
(05 Mar 2000)
selenium compounds Inorganic compounds that contain selenium as an integral part of the molecule.
(12 Dec 1998)
pyrvinium compounds <chemical> Pharmacological action: antinematodal agent.
(12 Dec 1998)
silicon compounds Inorganic compounds that contain silicon as an integral part of the molecule.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Daphnis and Chloe
    ´ÙÇÁ´Ï½º¿Í Ŭ·Î¿¡(2-3¼¼±â°æ ±×¸®½ºÀÇ ¸ñ°¡ÀûÀÎ À̾߱⠼ÓÀÇ ¼øÁøÇÑ ¿¬Àεé)
  • Darby and Joan
    (¹Î¿äÁßÀÇ ³ëºÎºÎ¿¡¼­);ÀÇÁÁÀº ´ÄÀº ºÎºÎ
  • Dark and Bloody Ground
    (¹Ì)KentuckyÁÖÀÇ º°¸í(ÃʱâÀÇ Àεð¾ð°úÀÇ ÀüÅõ¿Í °ü·ÃµÈ ȣĪ)
  • E.and P.
    extraordinary and plenipotentiary Ư¸í Àü±ÇÀÇ
  • Economic and Social Council
    =ECOSOC
  • Food and Agriculture Organization
    (À¯¿£) ½Ä·® ³ó¾÷ ±â±¸
  • Food and Drug Administration
    ½Äǰ ÀǾ౹(º¸°Ç ±³À° º¹Áö¼ºÀÇ ÀϺÎ)
  • Foreign and Commonwealth Office
    ¿Ü¹« ¿¬¹æ¼º
  • Gog and Magog
    °î°ú ¸¶°î(»çÅÁ¿¡ ¹ÌȤµÇ¾î ÇÏ´Ã ³ª¶ó¿¡ ´ëÇ×ÇÏ´Â µÎ³ª¶ó)
  • H and C
    Çì·ÎÀÎ(heroin)°ú ÄÚÄ«ÀÎ(cocaine)À» ¼¯Àº °Í
  • Hereford and Worcester
    À×±Û·£µå ¼­ºÎÀÇ ÁÖ(1974³â ½Å¼³)
  • International Bank for Reconstruction and Development
    ±¹Á¦ ºÎÈï°³¹ßÀºÇà(IBRD)ÅëĪ(the world bank)
  • Jekyll and Hyde
    2ÁßÀΰÝÀÚÀÇ;2Áß ÀΰÝÀûÀÎ
  • Punch and Judy
    Àͻ콺·¯¿î ¿µ±¹ÀÇ ÀÎÇü±Ø
  • R&D,R.and D.
    research and development ¿¬±¸ °³¹ß
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á